{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:32:31Z","timestamp":1776882751010,"version":"3.51.2"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2019,2]]},"abstract":"Summary<\/jats:title>Background<\/jats:title>Intravenous micafungin has been reported as a treatment alternative in patients with chronic pulmonary aspergillosis (CPA<\/jats:styled-content>) where long\u2010term oral triazole therapy is unfeasible.<\/jats:p><\/jats:sec>Objectives<\/jats:title>We evaluated the safety and efficacy of micafungin administered via the outpatient parenteral antimicrobial therapy (OPAT<\/jats:styled-content>) service for the treatment of CPA<\/jats:styled-content>.<\/jats:p><\/jats:sec>Methods<\/jats:title>We included all CPA<\/jats:styled-content> patients who received micafungin via OPAT<\/jats:styled-content> between April 2016 and March 2018. Data on adverse events and line\u2010related complications, and Quality of Life (QoL) scores at the start of micafungin course and 3\u00a0months later were extracted. Improvements in QoL<\/jats:styled-content> were defined as an improvement of \u22654 points in at least one modality (symptom, impact, activity, total) in the St George's QoL<\/jats:styled-content> score. A stable QoL<\/jats:styled-content> score was defined as a change in score of <4 points in either direction whilst deterioration was defined as an increase of \u22654 points.<\/jats:p><\/jats:sec>Results<\/jats:title>There were 20 OPAT<\/jats:styled-content> episodes involving 18 patients with a median duration of micafungin therapy of 21 (range: 4\u2010248) days. Improvement or stability in the symptoms, activity, impact and total score was seen in 14 (78%), 12 (67%), 9 (50%) and 9 (50%) of the patients, respectively. However, half of the patients reported deterioration in the impact domain and total scores. By self\u2010assessment, patients who categorised themselves as \u201cpoor\u201d were comparable at the start of OPAT<\/jats:styled-content> and at 3\u00a0months (43% vs 50%, McNemar's P<\/jats:italic>\u00a0=\u00a00.7). Adverse events attributable to micafungin were recorded in 3 (14.3%) episodes.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Micafungin may be safely administered via an OPAT<\/jats:styled-content> service. Micafungin therapy was associated with an improvement or stability in QoL scores in at least 50% of the patients across the four domains.<\/jats:p><\/jats:sec>","DOI":"10.1111\/myc.12857","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T13:18:38Z","timestamp":1538227118000},"page":"152-156","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Micafungin may be safely administered as outpatient parenteral antimicrobial therapy for chronic pulmonary aspergillosis"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6009-2707","authenticated-orcid":false,"given":"Akaninyene A.","family":"Otu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine University of Calabar Calabar Cross River State Nigeria"},{"name":"ECMM Centre of Excellence in Clinical and Laboratory Mycology and Clinical Studies The National Aspergillosis Centre Wythenshawe Hospital Manchester University NHS Foundation Trust Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-8517","authenticated-orcid":false,"given":"Felix","family":"Bongomin","sequence":"additional","affiliation":[{"name":"ECMM Centre of Excellence in Clinical and Laboratory Mycology and Clinical Studies The National Aspergillosis Centre Wythenshawe Hospital Manchester University NHS Foundation Trust Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Bazaz","sequence":"additional","affiliation":[{"name":"ECMM Centre of Excellence in Clinical and Laboratory Mycology and Clinical Studies The National Aspergillosis Centre Wythenshawe Hospital Manchester University NHS Foundation Trust Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Harris","sequence":"additional","affiliation":[{"name":"ECMM Centre of Excellence in Clinical and Laboratory Mycology and Clinical Studies The National Aspergillosis Centre Wythenshawe Hospital Manchester University NHS Foundation Trust Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Denning","sequence":"additional","affiliation":[{"name":"ECMM Centre of Excellence in Clinical and Laboratory Mycology and Clinical Studies The National Aspergillosis Centre Wythenshawe Hospital Manchester University NHS Foundation Trust Manchester UK"},{"name":"Faculty of Biology, Medicine and Health The University of Manchester Manchester UK"},{"name":"Manchester Academic Health Science Centre Education and Research Centre Wythenshawe Hospital Manchester University NHS Foundation Trust Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Kosmidis","sequence":"additional","affiliation":[{"name":"ECMM Centre of Excellence in Clinical and Laboratory Mycology and Clinical Studies The National Aspergillosis Centre Wythenshawe Hospital Manchester University NHS Foundation Trust Manchester UK"},{"name":"Faculty of Biology, Medicine and Health The University of Manchester Manchester UK"},{"name":"Manchester Academic Health Science Centre Education and Research Centre Wythenshawe Hospital Manchester University NHS Foundation Trust Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/376526"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-015-0388-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-017-0304-7"},{"key":"e_1_2_8_5_1","first-page":"688","article-title":"Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study","volume":"49","author":"Kohno S","year":"2011","journal-title":"Med Mycol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-012-0391-x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701278386"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00583-2015"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0014"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00063702"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.6.1321"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193732"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.06.001"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2010.08.005"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1754-z"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12857","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:36:41Z","timestamp":1694698601000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1111\/myc.12857"],"URL":"https:\/\/doi.org\/10.1111\/myc.12857","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,19]]},"assertion":[{"value":"2018-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}